Ophthalmology Times: Key Findings from Retina Society 2024 on ONL-1204 for Rhegmatogenous Retinal Detachment
Ophthalmology Times: Insightful Findings on ONL-1204
At the Retina Society 2024 meeting in Lisbon, Dr. Durga Borkar presented pivotal results from the phase 2 clinical trial of ONL-1204 for rhegmatogenous retinal detachment. This novel agent, designed to inhibit the FAS receptor, addresses both cell death and inflammation, crucial for patients experiencing this type of detachment even with timely surgical interventions.
Study Design and Results
The phase 2 study enrolled participants six months ahead of schedule, randomizing them into two dosage groups of ONL-1204, either 50 micrograms or 200 micrograms, administered as a single intravitreal injection. The procedure was performed alongside standard surgical repairs, with follow-ups extending over six months.
- Primary Endpoint: Contrast sensitivity results were comparable across treatment groups.
- Noteworthy Outcomes: Patients with greater than 8 days of macula off status demonstrated substantial visual benefits, particularly pseudofacic patients.
- Conclusion of Results: These findings promote the potential of ONL-1204 as a significant adjunct therapy for improving visual outcomes in challenging cases of rhegmatogenous retinal detachment.
Implications for Future Research
The results indicate a promising avenue for further examination, with Dr. Borkar emphasizing the importance of additional subgroup analyses and impending discussions with the FDA regarding future clinical trial steps.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.